Deutetrabenazine Patent Expiration
Deutetrabenazine is Used for managing movement disorders associated with neurological conditions. It was first introduced by Teva Branded Pharmaceutical Products R And D Llc
Deutetrabenazine Patents
Given below is the list of patents protecting Deutetrabenazine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Austedo Xr | US11311488 | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof | Jun 10, 2041 | Teva |
| Austedo |
US11179386 (Pediatric) | Analogs of deutetrabenazine, their preparation and use | Sep 15, 2038 | Teva Branded Pharm |
| Austedo |
US11813232 (Pediatric) | Analogs of deutetrabenazine, their preparation and use | Sep 15, 2038 | Teva Branded Pharm |
| Austedo Xr |
US11179386 (Pediatric) | Analogs of deutetrabenazine, their preparation and use | Sep 15, 2038 | Teva |
| Austedo Xr |
US11813232 (Pediatric) | Analogs of deutetrabenazine, their preparation and use | Sep 15, 2038 | Teva |
| Austedo | US11179386 | Analogs of deutetrabenazine, their preparation and use | Mar 15, 2038 | Teva Branded Pharm |
| Austedo | US11813232 | Analogs of deutetrabenazine, their preparation and use | Mar 15, 2038 | Teva Branded Pharm |
| Austedo Xr | US11179386 | Analogs of deutetrabenazine, their preparation and use | Mar 15, 2038 | Teva |
| Austedo Xr | US11813232 | Analogs of deutetrabenazine, their preparation and use | Mar 15, 2038 | Teva |
| Austedo |
US10959996 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US11357772 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US11446291 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US11564917 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US11648244 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US12016858 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo Xr |
US10959996 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US11357772 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US11446291 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US11564917 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US11648244 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US12016858 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo | US10959996 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US11357772 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US11446291 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US11564917 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US11648244 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US12016858 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo Xr | US10959996 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US11357772 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US11446291 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US11564917 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US11648244 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US12016858 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo |
US11666566 (Pediatric) | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo |
US9233959 (Pediatric) | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo |
US9296739 (Pediatric) | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo |
US9550780 (Pediatric) | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo |
US9814708 (Pediatric) | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo Xr |
US9550780 (Pediatric) | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva |
| Austedo | US11666566 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo | US9233959 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo | US9296739 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo | US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo | US9814708 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo Xr | US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva |
| Austedo |
US8524733 (Pediatric) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | Oct 03, 2031 | Teva Branded Pharm |
| Austedo Xr |
US8524733 (Pediatric) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | Oct 03, 2031 | Teva |
| Austedo | US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | Apr 03, 2031 | Teva Branded Pharm |
| Austedo Xr | US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | Apr 03, 2031 | Teva |
Deutetrabenazine's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List